fbpx

molecules of the month

AZD1656

oral glucokinase activator

Ph. II in renal transplant patients with DM2

AZD1092 opt. to avoid Ames test liability

Sci. Transl. Med.

AstraZeneca, Gothenburg, SE

AZD1656 chemical structure oral glucokinase activator - AstraZeneca, Gothenburg, SE
5 mins read

Context. AZD1656 (AstraZeneca)is an oral glucokinase (GK) activator (GKA) for hyperglycemia in type 2 diabetes mellitus. Despite GK being first reported more than 50 years ago and subsequent extensive research efforts, a GKA is yet to be approved. Most GKAs have failed in clinical development owing to an increased risk of hypoglycemia and gradual loss of efficacy. Consequently, alternative strategies such as the development of hepatoselective molecules and partial activation of the enzyme have been tried, with some of these agents still in clinical development. Previously, we covered dorzagliatin (Hua Medicine), a hepatic and pancreatic dual-acting full GKA that is currently the most advanced in the class. AZD1656, a full GKA, was first reported 10 years ago and has been…


request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.


already a member? log in: